RFK Jr. Goes Full Tinfoil, Pledges to Stop Chemtrails in Latest Dr. Phil Interview https://gizmodo.com/rfk-jr-goes-ful...trails-in-latest-dr-phil-interview-2000596357
Flu vaccinations go down, children's deaths go up. You can explain that, but you may get arrested, and deported to an El Salvador death camp for doing so. 216 US kids have died from the flu this season — the most in 15 years, CDC says The flu vaccination rate for U.S. children has plummeted from about 64% five years ago to 49% this season — a likely contributor to the increase in deaths. https://www.nbclosangeles.com/news/national-international/cdc-child-flu-death-count/3692165/
RFK Jr. is constantly spewing lies and conspiracy nonsense. He is not fit to serve in a position of responsibility. RFK Jr. Spews Wild Anti-Vax Theories As Measles Cases Surge While the U.S. hit 1,000 cases of measles for the first time in 30 years, RFK Jr. is claiming MMR vaccines are made from “aborted fetuses.” https://www.thedailybeast.com/rfk-jr-spews-batsht-anti-vax-theories-as-measles-cases-surge/
The Trump administration and Kennedy HHS has a policy of not warning the public and medical community about disease outbreaks. This completely undermines public health. Diseases are spreading. The CDC isn't warning the public like it was months ago NPR - https://tinyurl.com/h8y3fpbv
Wake me up when Columbia contributes anything to the world other than cocaine. What in the hell is Columbia doing about preventable disease? Where is Columbia's CDC. I asked AI if there are any Columbian Nobel Prize winners in medicine or science. This is what AI said, "No, as of my last update, no Colombian scientist or medical doctor has won a Nobel Prize in Physiology or Medicine, Physics, or Chemistry." Is Kangaroo Mother Care really the only contribution that Columbia has made? That's it? Oh, I get it. The Columbian version of the CDC is so incompetent that Columbians have to rely on another country. So, STFU.
Glass house! AI said: Systematic Failures in Colombia's National Health Regulatory System: An Analysis of INVIMA's Administrative and Oversight Shortcomings Colombia's National Institute of Medicine and Nutritional Oversight (INVIMA), the country's primary health regulatory agency equivalent to the United States' FDA and CDC, has experienced a series of significant operational and ethical failures that have compromised public health protection and regulatory integrity. These failures span multiple domains including systematic corruption involving bribery for product certification, critical cybersecurity vulnerabilities that disrupted essential regulatory functions, inadequate oversight of clinical research facilities leading to unethical human experimentation, and broader enforcement gaps that allow unsafe pharmaceutical practices to persist. The documented incidents reveal not isolated mistakes but rather systemic weaknesses in Colombia's health regulatory infrastructure that parallel and sometimes exceed regulatory failures observed in other developing nations' health agencies. Corruption and Bribery in Product Certification Systematic Bribery Schemes within INVIMA Colombia's health regulatory system has been severely compromised by systematic corruption involving the illegal certification of health products in exchange for bribes. Evidence emerged in 2019 showing INVIMA personnel accepting financial and material incentives to approve health products without proper regulatory review1. The corruption scandal centered on inappropriate relationships between INVIMA officials and pharmaceutical companies, with documented cases revealing a culture of bribery that extended throughout the organization. The most damaging evidence consisted of WhatsApp communications between Alicia Celis, an INVIMA official responsible for product licensing, and Claudia Lised Peñaranda, director of a Medellin-based company selling anti-arthritis gels1. These messages provided clear documentation of systematic bribery, with Peñaranda thanking Celis for "managing" certification cases and explicitly offering financial and material rewards for regulatory approval. The communications revealed that external lawyers had been less effective at obtaining approvals compared to direct bribery of INVIMA officials, suggesting that corruption had become the preferred method for securing regulatory clearance. Impact on Regulatory Integrity and Public Safety The bribery scandal exposed fundamental weaknesses in INVIMA's internal oversight mechanisms and quality control procedures. One particularly concerning case involved a businessman who was initially denied certification by INVIMA through normal regulatory channels but subsequently received approval after bribes were paid1. This pattern demonstrates how corruption undermined legitimate regulatory processes designed to protect public health, allowing potentially unsafe or ineffective products to reach Colombian consumers. The systematic nature of these bribes indicates that corruption was not limited to isolated incidents but represented a widespread institutional failure that compromised the agency's core mission of ensuring drug and medical device safety. Cybersecurity Vulnerabilities and System Failures Major Cyber Attack Disruptions INVIMA has experienced repeated cybersecurity failures that have severely disrupted its regulatory operations and compromised its ability to fulfill essential public health functions. In October 2022, the agency suffered a significant cyber attack that disabled its website and all connections to both physical and virtual servers, effectively paralyzing most regulatory activities5. The attack was so severe that INVIMA was forced to issue Resolution 2022600000, implementing emergency measures that suspended critical proceedings within the foodstuff, medicine, cosmetics, and medical device offices through October 31, 2022. The cyber attack forced INVIMA to implement emergency workarounds for essential regulatory functions, including requiring import authorizations for vital and unavailable medicines to be processed through email rather than secure digital systems5. This degradation of regulatory infrastructure created significant risks for pharmaceutical supply chain integrity and potentially delayed access to critical medications. The fact that INVIMA described this as occurring "again" suggests a pattern of cybersecurity vulnerabilities that the agency has failed to adequately address despite previous incidents. Operational Continuity and Public Health Implications The extended disruption of INVIMA's digital infrastructure highlighted critical weaknesses in the agency's contingency planning and cybersecurity preparedness. The suspension of routine regulatory activities for nearly a month created significant risks for public health protection, as new drug approvals, safety monitoring, and quality control inspections were either delayed or conducted through less secure emergency procedures5. The attack's impact on the agency's ability to monitor pharmaceutical imports and releases of drug batches created potential vulnerabilities in Colombia's drug supply chain that could have been exploited by bad actors seeking to introduce counterfeit or substandard medications. Clinical Trial Oversight and Research Ethics Failures Unauthorized Human Experimentation INVIMA has demonstrated severe failures in its oversight of clinical research, allowing unauthorized and potentially dangerous human experimentation to occur without proper regulatory approval or ethical review. In 2023, the agency was forced to halt clinical research at a US-funded facility after discovering multiple serious violations of research ethics and regulatory requirements6. The violations were so extensive that they represented a systematic failure of INVIMA's clinical trial oversight responsibilities. The facility was operating without INVIMA certification in Good Clinical Practices (GCP) and was conducting clinical trials without mandatory approvals from both INVIMA and institutional ethics committees6. Perhaps most concerning, the facility was conducting studies without obtaining written informed consent from participants, a fundamental violation of international research ethics standards. Additionally, some clinical studies were being led by non-physicians, and other researchers were not properly registered as health professionals, indicating a complete breakdown in credentialing and oversight procedures. Ethical Violations and Participant Safety The clinical research violations discovered at the facility revealed disturbing patterns of exploitation and endangerment of research participants. Study participants were being paid 250,000 pesos (approximately $60), which violated local regulations designed to prevent coercion and ensure voluntary participation6. More seriously, study designs appeared to deliberately expose previously healthy individuals to disease in order to measure vaccine immunogenicity, without implementing proper risk controls or following established safety procedures for such interventions. The facility had been publishing scientific papers describing human studies that had been conducted without any regulatory approval, while falsely claiming approval from ethics committees that had never actually reviewed the research protocols6. This pattern of deception extended to the international scientific community and represented a serious breach of research integrity that could have influenced other researchers and policy makers based on unethically obtained data. INVIMA's failure to detect and prevent these violations despite the facility's public dissemination of research results demonstrates significant weaknesses in the agency's monitoring and enforcement capabilities. Broader Regulatory Enforcement Deficiencies Systemic Oversight Gaps The documented failures at INVIMA reflect broader systemic problems in Colombia's pharmaceutical regulatory system that extend beyond individual incidents of corruption or cyberattacks. The agency's inability to detect ongoing clinical research violations despite published scientific papers describing unauthorized human studies suggests fundamental weaknesses in its monitoring and surveillance capabilities6. These gaps in oversight create opportunities for both deliberate fraud and inadvertent safety failures that could compromise public health protection. The pattern of failures across multiple domains - from bribery in product certification to unauthorized clinical research - indicates that INVIMA lacks robust internal controls and quality assurance mechanisms necessary for effective health regulation. The agency's vulnerability to both external cyber attacks and internal corruption suggests insufficient investment in both technological infrastructure and institutional integrity measures. These systemic weaknesses potentially compromise Colombia's entire pharmaceutical regulatory framework and could undermine international confidence in the safety and efficacy of Colombian-approved medical products. Conclusion The documented failures of Colombia's INVIMA represent serious systemic problems that extend far beyond isolated incidents of misconduct or technical difficulties. The convergence of corruption in product certification, cybersecurity vulnerabilities, and inadequate clinical research oversight reveals an agency struggling with fundamental institutional weaknesses that compromise its ability to protect public health effectively. These failures have potentially allowed unsafe products to reach consumers, disrupted access to essential medications, and permitted unethical human experimentation to occur without proper oversight. The systematic nature of these problems suggests that meaningful reform will require comprehensive institutional changes rather than superficial adjustments to existing procedures. INVIMA's failures highlight the critical importance of robust regulatory infrastructure, adequate cybersecurity measures, and strong ethical oversight mechanisms in protecting public health. Without significant improvements in these areas, Colombia's health regulatory system will continue to face risks that could undermine both domestic public health protection and the country's reputation in international pharmaceutical markets.
I'm not Colombian. Ireland and Denmark have I'm sure a disproportionate enough number of Nobel Prizes pro-rata? Sweden have a lot of course but they are cheaters. I am also technically American but we keep that quiet.
Those studies cited by Kennedy and his clowns -- yeah, they mostly don't exist or are being completely misinterpreted. The MAHA Report Cites Studies That Don’t Exist The Trump administration’s “Make America Healthy Again” report misinterprets some studies and cites others that don’t exist, according to the listed authors. https://www.notus.org/health-science/make-america-healthy-again-report-citation-errors